Trametinib tablet

DRUG6 trials

Sponsors

GlaxoSmithKline, Stanford University, University Health Network, Toronto, Medical University of Warsaw, Tianjin Medical University Second Hospital

Conditions

Arterial DiseaseArteriovenous MalformationsCancerCardiomegalyNoonan SyndromePrecision MedicineSolid TumorVascular Anomalies

Phase 1

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

CompletedNCT01647659

GlaxoSmithKlineCancer

Start: 2012-07-30End: 2012-11-12Updated: 2017-11-13

Trametinib Treatment for Complicated Vascular Anomalies

Active, not recruitingNCT07072403

West China HospitalVascular Anomalies

Start: 2025-07-07End: 2027-09-01Target: 20Updated: 2025-07-22

Phase 2

Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

Stanford UniversityArterial Disease, Venous Malformation

Start: 2020-12-01End: 2024-12-31Target: 30Updated: 2023-06-12

Pilot Study on Trametinib for Surgical Unruptured AVMs

University Health Network, TorontoArteriovenous Malformations

Start: 2024-01-30End: 2025-11-30Target: 10Updated: 2024-05-30

MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

RecruitingNCT06555237

Medical University of WarsawCardiomegaly, Noonan Syndrome

Start: 2024-08-01End: 2026-12-01Target: 40Updated: 2024-08-15

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

RecruitingNCT06739395

Tianjin Medical University Second HospitalPrecision Medicine, Solid Tumor

Start: 2024-11-01End: 2027-05-01Target: 300Updated: 2024-12-18

Related Papers

Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome.

2025-02-183 citations